title: Synthesis and in vitro study of cisplatin-loaded Fe3O4 nanoparticles modified with PLGA-PEG6000 copolymers in treatment of lung cancer.
abstract: In the field of cancer therapy, magnetic nanoparticles modified with biocompatible copolymers are promising vehicles for the delivery of hydrophobic drugs such as Cisplatin. The major aim of this effort was to evaluate whether Cisplatin-Encapsulated magnetic nanoparticles improved the anti-tumour effect of free Cisplatin in lung cancer cells. The PLGA-PEG triblock copolymer was synthesised by ring-opening polymerisation of d,l-lactide and glycolide with polyethylene glycol (PEG6000) as an initiator. The bulk properties of these copolymers were characterised using Fourier transform infrared spectroscopy. Cisplatin-loaded nanoparticles (NPs) were prepared by double emulsion solvent evaporation technique and were characterised for size, drug entrapment efficiency (%), drug content (% w/w), and surface morphology. In vitro release profile of cisplatin-loaded NP formulations was determined. Cytotoxic assays were evaluated in lung carcinoma (A549)-treated cells by the MTT assay technique. In addition, the particles were characterised by X-ray powder diffraction, scanning electron microscopy, Fourier transform infrared spectroscopy, and vibrating sample magnetometry. The anti-proliferative effect of Cisplatin appeared much earlier when the drug was encapsulated in magnetic nanoparticles than when it was free. Cisplatin-Encapsulated magnetic nanoparticles significantly enhanced the decrease in IC50 rate. The in vitro cytotoxicity test showed that the Fe3O4-PLGA-PEG6000 magnetic nanoparticles had no cytotoxicity and were biocompatible. The chemotherapeutic effect of free Cisplatin on lung cancer cells is improved by its encapsulation in modified magnetic nanoparticles. This approach has the prospective to overcome some major limitations of conventional chemotherapy and may be a promising strategy for future applications in lung cancer therapy.
authors.affiliation: Drug Applied Research Center, Tabriz University of Medical Sciences , Tabriz , Iran .
authors.forename: Kazem
authors.initials: K
authors.lastname: Nejati-Koshki
authors.forename: Mehran
authors.initials: M
authors.lastname: Mesgari
authors.forename: Eommolbanin
authors.initials: E
authors.lastname: Ebrahimi
authors.forename: Farhad
authors.initials: F
authors.lastname: Abbasalizadeh
authors.forename: Sedigeh
authors.initials: S
authors.lastname: Fekri Aval
authors.forename: Amir Ahmad
authors.initials: AA
authors.lastname: Khandaghi
authors.forename: Mozhgan
authors.initials: M
authors.lastname: Abasi
authors.forename: Abolfazl
authors.initials: A
authors.lastname: Akbarzadeh
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000737:chemistry / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D005290:Ferric Compounds / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry / Q000494:pharmacology; D008175:Lung Neoplasms / Q000188:drug therapy*; D058185:Magnetite Nanoparticles / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000737:chemistry / Q000494:pharmacology; D011100:Polyglycolic Acid / Q000737:chemistry / Q000494:pharmacology; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer
chemical_list: D000970:Antineoplastic Agents; D005290:Ferric Compounds; D058185:Magnetite Nanoparticles; C000499:ferric oxide; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D011092:Polyethylene Glycols; D002945:Cisplatin
keywords: Cisplatin; PLGA-PEG; drug delivery; lung cancer; magnetic nanoparticles